AbbVie ABBV Linzess — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's linzess — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's linzess — net revenues?
- AbbVie (ABBV) reported linzess — net revenues of $283M in Q1 2026.
- How has AbbVie's linzess — net revenues changed year-over-year?
- AbbVie's linzess — net revenues increased by 91.2% year-over-year, from $148M to $283M.
- What is the long-term trend for AbbVie's linzess — net revenues?
- Over 4 years (2021 to 2025), AbbVie's linzess — net revenues has grown at a -3.3% compound annual growth rate (CAGR), from $1.04B to $907M.
- What does linzess — net revenues mean?
- This metric represents the total net sales generated by the Linzess/Constella product line, a key gastrointestinal therapeutic offering. It reflects the gross revenue adjusted for returns, rebates, and discounts associated with the distribution and sale of this specific pharmaceutical asset. Monitoring this figure provides insight into the market demand and commercial performance of the company's gastrointestinal portfolio.